Jasmonate derivative compounds, pharmaceuticals compounds and methods of use thereof

1. A compound of Formula I:

wherein:

n is 0, 1, or 2;

R 1 is OH, C 1 to C 12 alkoxy, C 1 to C 12 substituted alkoxy, aryloxy, O-glucosyl or imino;

R 2 is OH, C 1 to C 12 alkoxy, C 1 to C 12 substituted alkoxy, O-glucosyl, oxo, alkyl or imino;

R 3 , R 4 , R 5 , R 6 , R 7 , A, B, C, D and E are each independently H, halogen selected from the group consisting of bromo, iodo, fluoro and chloro, OH, C 1 to C 12 alkoxy, C 1 to C substituted alkoxy, aryloxy, O-glucosyl, C 1 to C 12 alkyl or C 1 to C 12 substituted alkyl; provided that at least one of R 6 and R 7 is selected from the group consisting of bromo, iodo, fluoro and chloro;

wherein R 1 and R 2 , or R 1 and R 4 may form together a lactone which is optionally substituted;

wherein the bonds between C 3 :C 7 , C 4 :C 5 , and C 9 :C 10 may independently be double bonds or single bonds;

or a derivative of said formula, wherein the derivative has at least one of the following: a lower acyl side chain at C 3 (free acid or ester or conjugate), a keto or hydroxy (free hydroxy or ester) moiety at the C 6 carbon, or an n-pentenyl or n-pentyl side chain at C 7 ;

including salts, hydrates, solvates, polymorphs, optical isomers, enantiomers, diastereomers, and mixtures thereof.

2. The compound of claim 1 , wherein the bond between C 9 and C 10 is a single bond.

3. The compound of claim 1 , wherein R 2 is oxo.

4. The compound of claim 1 , wherein each of A, B, R 6 and R 7 is selected from bromo, iodo, fluoro and chloro.

5. The compound of claim 1 , wherein R 1 is alkoxy.

6. The compound of claim 1 , wherein R 3 , R 4 and R 5 are each H.

7. The compound of claim 1 , wherein C, D and E are each H.

8. The compound of claim 1 , wherein: n is 0; the bonds between C 3 :C 7 , C 4 :C 5 , and C 9 :C 10 are single bonds; R 1 is methoxy; R 2 is oxo; R 3 , R 4 , R 5 , A, B, C, D and E are each H; and R 6 and R 7 are each bromo.

9. The compound of claim 1 , wherein: n is 0; the bonds between C 3 :C 7 , C 4 :C 5 , and C 9 :C 10 are single bonds; R 1 is methoxy; R 2 is O bound through a double bond to the carbon in position 6 thereby forming a carbonyl group; R 3 , R 1 , R 5 , C, D and E are each H; and A, B, R 6 and R 7 are each bromo.

10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as an active ingredient a compound of claim 1 .

11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as an active ingredient a compound of claim 8 .

12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as an active ingredient a compound of claim 9 .

13. A method for reduction of the growth of cancer cells, comprising exposing the cancer cells to a therapeutically effective amount of a compound of claim 1 .

14. The method of claim 13 wherein the cancer is a mammalian cancer.

15. A method for the treatment of cancer comprising administering to the subject in need thereof a pharmaceutical composition containing as an active ingredient a therapeutically effective amount of the compound according to claim 1 .

16. A method for the treatment of cancer comprising administering to the subject in need thereof a pharmaceutical composition containing as an active ingredient a therapeutically effective amount of the compound according to claim 8 .

17. The method according to claim 15 , wherein the cancer is selected from the group consisting of carcinoma, sarcoma, adenoma, hepatocellular carcinoma, hepatoblastoma, rhabdomyosarcoma, esophageal carcinoma, thyroid carcinoma, ganglioblastoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphagiosarcoma, synovioama, Ewing's tumor, leimyosarcoma, rhabdotheliosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma, hematoma, bile duct carcinoma, melanoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell and non-small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocyoma, medulloblastoma, craniopharyngioma, ependynoma, pinealoma, retinoblastoma, rectal carcinoma, cancer of the thyroid, head and neck cancer, brain cancer, neuroblastoma, cancer of the endometrium, lymphoproliferative diseases, hematopoietic malignancies including all types of leukemia and lymphoma including: acute myelogenous leukemia, acute myelocytic leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, mast cell leukemia, multiple myeloma, myeloid lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, as well as metastasis of all the above.

18. The method of claim 15 , wherein the cancer is selected from the group consisting of prostate cancer, breast cancer, skin cancer, colon cancer, lung cancer, pancreatic cancer, lymphoma, leukemia, head and neck cancer, kidney cancer, ovarian cancer, bone cancer liver cancer, melanoma and thyroid cancer.

19. The compound of claim 1 , wherein R 6 and R 7 are each F.

20. The compound of claim 1 , wherein R 6 and R 7 are each I.

21. The compound of claim 1 , wherein R 6 and R 7 are each Cl.

22. The compound of claim 1 , wherein R 6 and R 7 are each Br.

23. The compound of claim 1 , wherein one of R 6 and R 7 is Br and the other is OH.

24. The compound of claim 1 , wherein one of R 6 and R 7 is I and the other is OCH 3 .

25. A method for the treatment of cancer comprising administering to the subject in need thereof a pharmaceutical composition containing as an active ingredient a therapeutically effective amount of the compound of Formula I:

wherein:

n is 0, 1, or 2;

R 1 is OH, C 1 to C 12 alkoxy, C 1 to C 12 substituted alkoxy, aryloxy, O-glucosyl or imino;

R 2 is OH, C 1 to C 12 alkoxy, C 1 to C 12 substituted alkoxy, O-glucosyl, oxo, alkyl or imino;

R 3 , R 4 , R 5 , R 6 , R 7 , A, B, C, D and E are each independently H, halogen, OH, C to C alkoxy, C to C substituted alkoxy, aryloxy, O-glucosyl, C 1 to C 12 alkyl or C 1 to C 12 substituted alkyl;

wherein R 1 and R 2 , or R 1 and R 4 may form together a lactone which is optionally substituted;

wherein the bonds between C 3 :C 7 , C 4 :C 5 , and C 9 :C 10 may independently be double bonds or single bonds;

provided that at least one of R 3 , R 4 , R 5 , R 6 , R 7 , A, B, C, D or E is a halogen; and provided that, if A is the only halogen in the compound, that A is not fluoro;

or a derivative of said formula, wherein the derivative has at least one of the following: a lower acyl side chain at C 3 (free acid or ester or conjugate), a keto or hydroxy (free hydroxy or ester) moiety at the C 6 , carbon, or an n-pentenyl or n-pentyl side chain at C 7 ;

including salts, hydrates, solvates, polymorphs, optical isomers, enantiomers, diastereomers, and mixtures thereof.

26. The method of claim 25 , wherein the cancer is selected from the group consisting of carcinoma, sarcoma, adenoma, hepatocellular carcinoma hepatoblastoma, rhabdomyosarcoma, esophageal carcinoma, thyroid carcinoma, ganglioblastoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphagiosarcoma, synovioama, Ewing's tumor, leimyosarcoma, rhabdotheliosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma, hematoma, bile duct carcinoma, melanoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell and non-small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocyoma, medulloblastoma, craniopharyngioma, ependynoma, pinealoma, retinoblastoma, rectal carcinoma, cancer of the thyroid, head and neck cancer, brain cancer, neuroblastoma, cancer of the endometrium, lymphoproliferative diseases, hematopoietic malignancies including all types of leukemia and lymphoma including: acute myelogenous leukemia, acute myelocytic leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, mast cell leukemia, multiple myeloma myeloid lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, as well as metastasis of all the above.

27. A compound of Formula I:

wherein:

n is 0, 1 or 2;

R 1 is OH, C 1 to C 12 alkoxy, C 1 to C 12 substituted alkoxy, aryloxy, O-glucosyl or imino;

R 2 is OH, C 1 to C 12 alkoxy, C 1 to C 12 substituted alkoxy, O-glucosyl, oxo, alkyl or imino;

R 3 , R 4 , R 5 , R 6 , R 7 , A, B, C, D and E are each independently H, halogen, OH, C to C alkoxy, C to C substituted alkoxy, aryloxy, O-glucosyl, C 1 to C 12 alkyl or C 1 to C 12 substituted alkyl; provided that at least one of R 4 , R 5 , R 6 , R 7 , B, C, D or E is a halogen;

wherein R 1 and R 2 , or R 1 and R 4 may form together a lactone which is optionally substituted;

wherein the bonds between C 3 :C 7 , C 4 :C 5 , and C 9 :C 10 may independently be double bonds or single bonds;

or a derivative of said formula, wherein the derivative has at least one of the following: a lower acyl side chain at C 3 (free acid or ester or conjugate), a keto or hydroxy (free hydroxy or ester) moiety at the C 6 carbon, or an n-pentenyl or n-pentyl side chain at C 7 ;

including salts, hydrates, solvates, polymorphs, optical isomers, enantiomers, diastereomers, and mixtures thereof.

28. The compound of claim 27 , wherein the bond between C 9 and C 10 is a single bond.

29. The compound of claim 27 , wherein R 2 is oxo.

30. The compound of claim 27 , wherein R 1 is alkoxy.

31. The compound of claim 27 , wherein R 3 , R 4 and R 5 are each H.

32. The compound of claim 27 , wherein C, D and E are each H.

33. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as an active ingredient a compound of claim 27 .

34. A method for reduction of the growth of cancer cells, comprising exposing the cancer cells to a therapeutically effective amount of a compound of claim 27 .

35. A method for the treatment of cancer comprising administering to the subject in need thereof a pharmaceutical composition containing as an active ingredient a therapeutically effective amount of the compound according to claim 27 .

36. The method of claim 35 , wherein the cancer is selected from the group consisting of carcinoma, sarcoma, adenoma, hepatocellular carcinoma, hepatoblastoma, rhabdomyosarcoma, esophageal carcinoma, thyroid carcinoma, ganglioblastoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphagiosarcoma, synovioama Ewing's tumor, leimyosarcoma, rhabdotheliosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma, hematoma, bile duct carcinoma, melanoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell and non-small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocyoma, medulloblastoma, craniopharyngioma, ependynoma, pinealoma, retinoblastoma, rectal carcinoma, cancer of the thyroid, head and neck cancer, brain cancer, neuroblastoma, cancer of the endometrium, lymphoproliferative diseases, hematopoietic malignancies including all types of leukemia and lymphoma including: acute myelogenous leukemia, acute myelocytic leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, mast cell leukemia, multiple myeloma, myeloid lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma.